A pharmacy partner is the regulated dispensing and fulfilment layer that operates behind a digital health clinic — sourcing, dispensing, and delivering medicines to patients on the clinic’s behalf.
The choice is rarely treated as critical until it becomes one. This guide is the framework we’d want a clinic operator to use, whoever they end up choosing.
It’s a clinical-risk decision. Not a logistics one.
Most clinic operators evaluate pharmacy partners the way they’d evaluate a courier. Cost per order, despatch speed, geographic coverage. Those things matter — but they aren’t where the decision lives.
The pharmacy is the regulated entity in the chain. When a clinical incident happens — a wrong dose, a missed contraindication, a cold-chain failure, a prescription dispensed to the wrong patient — the pharmacy carries it. But the operating decisions that lead to those incidents are often made on the clinic side: the therapy area chosen, the patient group accepted, the protocol designed, the commercial pressure to scale fast.
The right pharmacy partner is the one structurally equipped to close the gap between commercially compliant and safe at scale. The wrong one is the one that simply does what it’s told.
That’s the lens worth bringing to the evaluation. Everything below follows from it.
Six criteria, in priority order.
Use them in the order shown. The earlier criteria are filters — if a partner fails them, the later ones don’t matter.
1Regulatory standing and clinical governance
Start here. Confirm GPhC registration. Confirm LegitScript certification if the partner dispenses prescription-only medicines. Confirm NHS DSPT assurance and ICO registration for data handling. Beyond the certificates: ask which superintendent pharmacist holds clinical responsibility, how often that person is involved in operational decisions, and what governance structure sits above the dispensing operation. Regulation is the floor. You want to understand how far above the floor the partner operates — and whether they can show you.
2Therapy-area depth, not general dispensing capacity
A generalist pharmacy that handles a thousand SKUs across every therapy area is structurally not the same as a partner that has built dedicated workflows for one. Weight management dispensing has different stock-control demands than ADHD; women’s health has different patient-communication demands than addiction. Ask how many patients the partner has supported in your specific therapy area, how many doses dispensed, and whether they operate a dedicated workflow for it. Generalist capability scales — but not safely, in scrutinised therapy areas.
3Supply-chain provenance
In high-scrutiny therapy areas, where medicines come from is as important as what’s dispensed. Ask the partner to evidence the source. Direct manufacturer relationships and licensed wholesaler relationships are the only acceptable answers. If a partner sources opportunistically across the secondary market to meet demand, that’s a structural risk you’ll inherit.
4Integration and operational visibility
If the pharmacy can’t tell you, in real time, where any given prescription is in the workflow, you can’t tell your patients. Ask about API integration with your prescribing or order management system. Ask about webhooks for prescription status, order status, and despatch. Ask what reporting is available at clinic, prescriber, and patient level. Operational visibility is what lets you scale without losing service quality.
5Service responsiveness — and what happens when it slips
Same-day despatch rates and dispensing accuracy figures are easy to claim. Ask for documented evidence. Ask for documented service response times — email, phone, escalation. Ask how the partner handles the moments where service slips: a stocked-out medicine, a missed delivery, a complaint. The honest answer to what happens when something goes wrong tells you more about the partnership than any pitch deck.
6What happens as volumes scale
A partner that handles 200 orders a day is not automatically the partner that handles 2,000. Ask how forecasting works — whether the partner aligns stock to clinic-level volume, whether trigger points exist for capacity planning, what the operational controls look like as volumes grow. Also ask, plainly: does the partner also operate a direct-to-patient brand in your therapy area? If yes, they are competing with you for the same patients. That isn’t a partnership; it’s a temporary arrangement.
Checklist
Questions to ask any partner.
Take this into any pharmacy partner conversation — including ours. The questions are designed to be answerable; if a partner avoids them, that's an answer too.
The shortlist questions
Eight questions, ordered to mirror the criteria above. Print them, take them into the room, and write the answers down.
- What is your GPhC registration number, and can you provide your LegitScript, NHS DSPT, and ICO standing?
- How many patients have you supported in our therapy area, and how many doses have you dispensed? Do you operate a dedicated workflow for it, or handle it as part of general fulfilment?
- Where do you source medicines for this therapy area? Can you evidence direct manufacturer or licensed wholesaler relationships?
- Do you integrate with our clinical or order management system via API? What status webhooks are available, and what reporting do you provide at clinic and prescriber level?
- What are your documented same-day despatch rates, dispensing accuracy, and service response times? Will you commit to them in writing?
- What is your forecasting and stock-alignment process when our volume changes? What happens to our patients if our orders triple in 90 days?
- Do you operate exclusively B2B, or do you also run a direct-to-patient brand in our therapy area?
- Do you operate to a named partner standard above the regulatory floor? What does qualification look like, and how is assurance maintained over the life of the partnership?
One integration, multiple markets.
Most clinics begin in one country and scale into others. The pharmacy decision repeats every time — new regulator, new supply chain, new integration. There's an alternative worth knowing about.
A single integration that opens access across the US, UK and EU.
Onescript is the sole UK clinical and pharmacy partner of Foundation Health — the digital health infrastructure company founded by Umar Afridi, co-founder and former CEO of Truepill, the pioneering US digital pharmacy platform. Foundation Health provides the infrastructure layer for direct-to-patient healthcare across multiple geographies; Onescript provides the UK clinical and pharmacy operations.
For clinics operating in more than one market, one Onescript integration opens access to that wider network — without the cost of re-procuring a pharmacy partner in every geography.
The short version
How Onescript answers these.
Onescript is GPhC-registered (9013068), LegitScript certified, NHS DSPT assured, and ICO registered. Weight management is our flagship therapy area — over 60,000 patients supported, more than 720,000 GLP-1 doses dispensed, operated through a dedicated dispensary with workflows engineered for the therapy area, not bolted onto a generalist operation. Medicines come from direct manufacturer and licensed wholesaler relationships only. The platform integrates via API. Operational visibility runs end-to-end: prescription, order, despatch, delivery. We operate exclusively B2B — we don't run a direct-to-patient brand, because partners that compete with their own clients aren't partners.
On the last question — the standard above the regulatory floor — we built one. It's called the 1° Standard: the partner qualification framework every clinic operating through Onescript is held to, and the one we hold ourselves to in return.